The Duke Human Vaccine Institute plays an integral role in modernizing flu vaccines.
Duke is the only institution to receive a contract in each of the three CIVICs components, including work to design and evaluate influenza vaccine approaches, manufacture and evaluate the safety and toxicity of vaccine platforms, and conduct clinical trials for influenza vaccines.
Duke Health is leading its first clinical trial under a large federal initiative to develop a new-generation flu vaccine.
Duke Human Vaccine Institute to Serve as National Coordinating Center in Fight Against Influenza, COVID-19 and Respiratory Viruses
DHVI receives $4.9 million grant from CDC to serve seven U.S. sites